RCKT vs. AUPH, CVAC, MLYS, PAHC, RCUS, WVE, SNDX, COLL, ELVN, and SYRE
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Aurinia Pharmaceuticals (AUPH), CureVac (CVAC), Mineralys Therapeutics (MLYS), Phibro Animal Health (PAHC), Arcus Biosciences (RCUS), Wave Life Sciences (WVE), Syndax Pharmaceuticals (SNDX), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.
Rocket Pharmaceuticals vs.
Rocket Pharmaceuticals (NASDAQ:RCKT) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, community ranking, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.
98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 24.8% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Aurinia Pharmaceuticals has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Rocket Pharmaceuticals currently has a consensus price target of $19.57, indicating a potential upside of 519.35%. Aurinia Pharmaceuticals has a consensus price target of $11.50, indicating a potential upside of 41.10%. Given Rocket Pharmaceuticals' higher possible upside, equities research analysts clearly believe Rocket Pharmaceuticals is more favorable than Aurinia Pharmaceuticals.
Rocket Pharmaceuticals has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.
In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 8 mentions for Rocket Pharmaceuticals and 7 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.63 beat Rocket Pharmaceuticals' score of 0.19 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.
Rocket Pharmaceuticals has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Aurinia Pharmaceuticals' return on equity of -4.41% beat Rocket Pharmaceuticals' return on equity.
Aurinia Pharmaceuticals received 167 more outperform votes than Rocket Pharmaceuticals when rated by MarketBeat users. Likewise, 73.41% of users gave Aurinia Pharmaceuticals an outperform vote while only 72.44% of users gave Rocket Pharmaceuticals an outperform vote.
Summary
Aurinia Pharmaceuticals beats Rocket Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Rocket Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rocket Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RCKT) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy RCKT Stock Free RCKT Stock Alerts